The Global Milbemycinoxime API Market was valued at USD 31.22 Million in 2025 and is projected to reach USD 49.96 Million by 2034, growing at a Compound Annual Growth Rate (CAGR) of 6.9% during the forecast period (2026–2034). This growth is fueled by the expanding global pet population, the rising standard of veterinary care, and the increasing adoption of preventative deworming protocols for companion animals worldwide.

As the veterinary pharmaceutical industry focuses on advanced parasiticide solutions, the spotlight is on the key active pharmaceutical ingredient (API) manufacturers who are driving innovation, quality, and supply chain reliability. In this blog, we profile the Top 10 Companies in the Milbemycinoxime API Industry—a mix of established chemical giants, specialized pharmaceutical producers, and innovators shaping the future of animal health.

---

🔟 1. JIANGSU LINGYUN PHARMACEUTICAL CO., LTD

Headquarters: Yancheng, Jiangsu, China
Key Offering: High-Purity Milbemycinoxime API (≥98%)

Jiangsu Lingyun Pharmaceutical is a prominent manufacturer of veterinary APIs, with a strong focus on milbemycinoxime. The company leverages advanced fermentation and chemical synthesis technologies to produce high-quality API that meets stringent international standards, supplying major veterinary pharmaceutical formulators globally.

Strategic Initiatives:

• Continuous process optimization for higher yield and purity

• Expansion of production capacity to meet growing global demand

• Investment in R&D for developing advanced antiparasitic formulations

Download FREE Sample Report: Milbemycinoxime API Market – View in Detailed Research Report

---

9️⃣ 2. Joincare Pharmaceutical Group Industry Co., Ltd.

Headquarters: Zhuhai, Guangdong, China
Key Offering: Milbemycinoxime API, Veterinary Pharmaceutical Intermediates

Joincare is a diversified pharmaceutical group with a significant presence in the veterinary API sector. Its robust manufacturing infrastructure and stringent quality control systems ensure a reliable supply of milbemycinoxime API to partners worldwide, supporting the production of effective deworming products.

Strategic Initiatives:

• Vertical integration from raw materials to finished API

• Focus on compliance with FDA, EMA, and other international regulatory standards

---

8️⃣ 3. Zhejiang Hisun Pharmaceutical Co., Ltd.

Headquarters: Taizhou, Zhejiang, China
Key Offering: Milbemycinoxime API, Active Pharmaceutical Ingredients

Zhejiang Hisun Pharmaceutical is a leading API manufacturer with extensive experience in fermentation-based products. The company’s expertise in macrolide antibiotics and antiparasitic agents positions it as a key supplier in the milbemycinoxime market, serving both domestic and international customers.

Strategic Initiatives:

• Advanced bioreactor technology for efficient fermentation processes

• Strategic partnerships with global animal health companies

---

7️⃣ 4. Hubei Honch Pharmaceutical Co., Ltd.

Headquarters: Wuhan, Hubei, China
Key Offering: Milbemycinoxime API, Custom Synthesis Services

Hubei Honch Pharmaceutical specializes in the research, development, and production of veterinary APIs. The company has established itself as a reliable source for high-purity milbemycinoxime, catering to the specific needs of formulation developers seeking consistent quality and supply.

Strategic Initiatives:

• Investment in green chemistry principles to improve sustainability

• Development of custom synthesis capabilities for specialized client requirements

Download FREE Sample Report: Milbemycinoxime API Market – View in Detailed Research Report

---

6️⃣ 5. Zhejiang Apeloa Kangyu Pharmaceutical Co., Ltd.

Headquarters: Jinhua, Zhejiang, China
Key Offering: Milbemycinoxime API, Pharmaceutical Raw Materials

As part of the Apeloa Group, this company benefits from extensive resources and a strong track record in pharmaceutical manufacturing. It produces milbemycinoxime API that is critical for formulating broad-spectrum parasiticide products for the companion animal market.

Strategic Initiatives:

• Implementation of continuous improvement processes in manufacturing

• Focus on achieving and maintaining cGMP certifications

---

5️⃣ 6. Qilu Pharmaceutical (Hainan) Co., Ltd.

Headquarters: Haikou, Hainan, China
Key Offering: Milbemycinoxime API, Veterinary Drug Substances

Qilu Pharmaceutical is a major player in the Chinese pharmaceutical industry with a growing footprint in veterinary medicines. The company’s Hainan facility focuses on producing high-quality APIs, including milbemycinoxime, leveraging modern production technologies and rigorous quality assurance.

Strategic Initiatives:

• Utilization of Hainan’s favorable policies for pharmaceutical export

• Expansion of API product portfolio to serve diverse market needs

---

4️⃣ 7. Lier Chemical Co., Ltd.

Headquarters: Sichuan, China
Key Offering: Milbemycinoxime Technical, Agrochemical and Veterinary APIs

Lier Chemical is a diversified chemical company with significant operations in the agrochemical and veterinary sectors. Its production capabilities for milbemycinoxime contribute to the supply of active ingredients used in popular deworming medications for pets.

Strategic Initiatives:

• Cross-sector application of chemical synthesis expertise

• Investment in environmental protection and waste treatment technologies

---

3️⃣ 8. Nanjing King-Pharm Pharmaceutical Technology Co., Ltd.

Headquarters: Nanjing, Jiangsu, China
Key Offering: Milbemycinoxime API, Pharmaceutical Intermediates

This specialized pharmaceutical technology company focuses on the development and production of high-value APIs. Nanjing King-Pharm has built a reputation for quality and reliability in the milbemycinoxime market, serving both domestic and international clients.

Strategic Initiatives:

• Strong R&D focus on process innovation and impurity profile control

• Collaborations with academic institutions for advanced research

---

2️⃣ 9. Zhejiang Huayi Pharmaceutical Co., Ltd.

Headquarters: Linhai, Zhejiang, China
Key Offering: Milbemycinoxime API, Fine Chemicals

Zhejiang Huayi Pharmaceutical is engaged in the manufacturing of APIs and fine chemicals for the veterinary and human health sectors. The company’s commitment to quality and consistency makes it a trusted supplier in the milbemycinoxime API supply chain.

Strategic Initiatives:

• Modernization of production facilities to enhance efficiency

• Expansion into regulated markets with high-quality standards

---

1️⃣ 10. Zhejiang Garden Biochemical Co., Ltd.

Headquarters: Jinhua, Zhejiang, China
Key Offering: Milbemycinoxime API, Vitamin and API Production

While primarily known for its vitamin production, Zhejiang Garden Biochemical has diversified into API manufacturing, including milbemycinoxime. The company applies its extensive biochemical engineering expertise to produce high-quality veterinary APIs for the global market.

Strategic Initiatives:

• Leveraging existing fermentation capabilities for new product lines

• Strategic focus on sustainable and efficient manufacturing processes

Get Full Report Here: Milbemycinoxime API Market – View in Detailed Research Report

---

🌍 Outlook: The Future of Milbemycinoxime API Is High-Quality and Compliant

The milbemycinoxime API market is undergoing a significant transformation. While demand continues to grow steadily, the industry is increasingly focusing on quality assurance, regulatory compliance, and supply chain stability rather than competing solely on price.

📈 Key Trends Shaping the Market:

• Shift towards API purity levels greater than 98% to meet stringent formulation requirements

• Increasing regulatory scrutiny and harmonization of veterinary drug standards globally

• Growing demand for combination therapies incorporating milbemycinoxime with other active ingredients

• Strategic partnerships between API manufacturers and formulation companies for supply chain security

Get Full Report Here: Milbemycinoxime API Market – View in Detailed Research Report

The companies listed above are not only supplying a critical veterinary API—they’re enabling the advancement of animal health and welfare worldwide.